

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10582304
Filing Date	2007-04-20
First Named Inventor	Kimura et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0166US1

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7115373	B2	2009-10-27	HASHIDA et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20090297501	A1	2009-12-03	IGAWA et al.	
	2	20030103979	A1	2003-06-05	LEUNG et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO97034632	WO		1997-09-25	LEUNG et al.		<input type="checkbox"/>
	2	WO03002607	WO	A1	2003-01-09	LEUNG et al.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10582304	
		Filing Date		2007-04-20	
		First Named Inventor		Kimura et al.	
		Art Unit		1643	
		Examiner Name		Anne Gussow	
		Attorney Docket Number		14875-0166US1	

	3	JP10508868	JP		1998-09-02	UCKUN et al.		<input type="checkbox"/>
	4	JP2005529616	JP		2005-10-06	DEVERAUX et al.		<input type="checkbox"/>
	5	WO02028894	WO		2002-04-11	KOMATANI et al.		<input type="checkbox"/>
	6	WO2005004912	WO		2005-01-20	NAKAMURA et al.		<input type="checkbox"/>
	7	WO2008007755	WO		2008-01-17	KIMURA et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	<input type="checkbox"/> T5
	1	SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," Current Opinion in Hematology, 12:444-450 (2005)	<input type="checkbox"/>
	2	U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages	<input type="checkbox"/>
	3	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed October 27, 2009, 4 pages	<input type="checkbox"/>
	4	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10582304
		Filing Date	2007-04-20
		First Named Inventor	Kimura et al.
		Art Unit	1643
		Examiner Name	Anne Gussow
		Attorney Docket Number	14875-0166US1

	5	BORDEN et al., "Lymphokines and Cytokines as Cancer Treatment," Cancer, 65:800-814 (1990)	<input type="checkbox"/>
	6	BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," CA Cancer J. Clin., 49:353-361 (1999)	<input type="checkbox"/>
	7	GRANZIERO et al., "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," Eur. J. Immunol., 29:1127-1138 (1999)	<input type="checkbox"/>
	8	U.S. EXAMINER ELLY GERALD STOICA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages	<input type="checkbox"/>
	9	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/548,727, mailed November 25, 2009, 29 pages	<input type="checkbox"/>
	10	FISH & RICHARDSON, Amendment in Reply to Action dated June 8, 2009 in U.S. App. Ser. No. 10/530,696, filed November 30, 2009, 10 pages	<input type="checkbox"/>
	11	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 1, 2009 in U.S. App. Ser. No. 11/547,747, filed November 30, 2009, 12 pages	<input type="checkbox"/>
	12	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 2, 2009, 4 pages	<input type="checkbox"/>
	13	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed December 8, 2009, 33 pages	<input type="checkbox"/>
	14	FISK et al., "Increased sensitivity of Adriamycin-selected Tumor Lines to CTL-mediated Lysis Results in Enhanced Drug Sensitivity," Cancer Res., 58:4790-4793 (1998)	<input type="checkbox"/>
	15	JALILI et al., "Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells," Blood (ASH Annual Meeting Abstracts), 118 (11):701a-702a (#2376) (2007)	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10582304
	Filing Date	2007-04-20
	First Named Inventor	Kimura et al.
	Art Unit	1643
	Examiner Name	Anne Gussow
	Attorney Docket Number	14875-0166US1

16	MELGUIZO et al., "Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells," <i>Neoplasma</i> , 50(2):91-96 (2003)	<input type="checkbox"/>
17	OZAKI et al., "Induction of myeloma cell death by a recombinant HLA class I-specific single-chain Fv diabody," <i>Dai 65 Nihon Ketsueki Gakkai, Dai 45 kai Nihon Ketsueki Gakkai Sokai, Osaka</i> (August 28-31, 2003)	<input checked="" type="checkbox"/>
18	OZAKI et al., "A recombinant HLA class I-specific single chain Fv diabody induces cell death in human lymphoid malignancies," <i>45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA</i> (December 6-9, 2003)	<input type="checkbox"/>
19	PRADOS et al., "Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase," <i>Neoplasma</i> , 53(3):226-231 (2006)	<input type="checkbox"/>
20	SEKIMOTO et al., "Eradication of human myeloma cells by a recombinant HLA class I-specific single chain Fv diabody," <i>45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA</i> (December 6-9, 2003)	<input type="checkbox"/>
21	SONNEVELD, "Multidrug resistance in haematological malignancies," <i>J. Intern. Med.</i> , 247:521-534 (2000)	<input type="checkbox"/>
22	TSUKAKOSHI, <i>New Pharmacology</i> , 3rd revised edition, Nankodo Co., Ltd., 557-568 (1997)	<input type="checkbox"/>
23	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2008/054443, dated May 27, 2008, 7 pages	<input type="checkbox"/>
24	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed January 7, 2010, 46 pages	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10582304
	Filing Date	2007-04-20
	First Named Inventor	Kimura et al.
	Art Unit	1643
	Examiner Name	Anne Gussow
	Attorney Docket Number	14875-0166US1

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.